Packaging signals in the 5′-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules

• Published in: Antiviral research 2011-10, Vol.92 (1), p.64-72
• Main Authors: Giannecchini, Simone, Wise, Helen M., Digard, Paul, Clausi, Valeria, Poggetto, Edoardo Del, Vesco, Liberio, Puzelli, Simona, Donatelli, Isabella, Azzi, Alberta
• Format: Article
• Language: English
• Subjects: Animals; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antisense; Antiviral activity; Antiviral agents; Antiviral Agents - pharmacology; Antiviral resistance; Biological and medical sciences; Cell Line; Disease resistance; Drug Resistance, Multiple, Viral; Fitness; Humans; Influenza A virus; Influenza A virus - drug effects; Influenza A virus - genetics; Influenza A virus - physiology; Influenza A Virus, H1N1 Subtype - drug effects; Influenza A Virus, H1N1 Subtype - genetics; Influenza A Virus, H1N1 Subtype - physiology; Influenza virus; Medical sciences; Mutation; Oligonucleotides; Packaging; Pharmacology. Drug treatments; phosphorothioate; Phosphorothioate Oligonucleotides - pharmacology; Polymerases-derived S-ON; Replication; RNA; RNA Replicase - genetics; RNA Replicase - metabolism; RNA, Viral - genetics; RNA, Viral - metabolism; Viral Proteins - genetics; Viral Proteins - metabolism; Virus Assembly - drug effects; Virus inhibition; Virus Replication - drug effects
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/j.antiviral.2011.06.013

► S-ON reproducing the packaging signal in the 5′ end of PB1 and PA segment of influenza A virus proved inhibitory. ► PB2-derived S-ON selection of an H1N1 strain generated resistant viruses with mutations in the PB1, PB2, PA and M1 segments. ► Reverse genetics study suggested that alterations to RNA function in the packaging regions of PB1 and PA were crucial. ► Other mutations induced by S-ON treatment were markedly deleterious to virus fitness. ► Packaging signals in the influenza A virus polymerase segments provide feasible targets for nucleic acid-based antivirals. In a previous study a 15-mer phosphorothioate oligonucleotide (S-ON) derived from the packaging signal in the 5′ end of segment 1 (PB2) of influenza A virus (designated 5–15b) proved markedly inhibitory to virus replication. Here we investigated whether analogous inhibitory S-ONs targeting the 5′ end of segments 2 (PB1) and 3 (PA) could be identified and whether viral resistance to S-ONs can be developed. Similar to our earlier result, 20-mer S-ONs reproducing the 5′ ends of segments 2 or 3 (complementary to the 3′-coding regions of PB1 and PA, respectively) exerted a powerful antiviral activity against a variety of influenza A virus subtypes in MDCK cells. Serial passage of the A/Taiwan/1/86 H1N1 strain in the presence of S-ON 5–15b or its antisense as5–15b analogue showed that mutant viruses with reduced susceptibility to the S-ON could indeed be generated, although the resistant viruses displayed reduced replicative fitness. Sequencing the resistant viruses identified mutations in the PB1, PB2, PA and M1 genes. Introduction of these changes into the A/PR/8/34 H1N1 strain by reverse genetics, suggested that alterations to RNA function in the packaging regions of segments 2 and 3 were important in developing resistance to S-ON inhibition. However, many of the other sequence changes induced by S-ON treatment were markedly deleterious to virus fitness. We conclude that packaging signals in the influenza A virus polymerase segments provide feasible targets for nucleic acid-based antivirals that may be difficult for the virus to evade through resistance mutations.